Karuna Therapeutics Inc
Change company Symbol lookup
Select an option...
KRTX Karuna Therapeutics Inc
SNSE Sensei Biotherapeutics Inc
ALGS Aligos Therapeutics Inc
SRRA Sierra Oncology Inc
ATOS Atossa Therapeutics Inc
OSMT Osmotica Pharmaceuticals PLC
SAND Sandstorm Gold Ltd
GRVI Grove Inc
STON Stonemor Inc
TK Teekay Corp
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is developing a pipeline of therapeutic programs to address symptoms associated with schizophrenia and psychosis associated with Alzheimer’s disease (AD), as well as various forms of pain. KarXT is a combination of xanomeline and trospium. KarXT combines xanomeline, a muscarinic agonist, with trospium, a muscarinic antagonist, to stimulate muscarinic receptors in the CNS. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms.

Price
Delayed
$124.67
Day's Change
0.055 (0.04%)
Bid
--
Ask
--
B/A Size
--
Day's High
125.49
Day's Low
121.22
Volume
(Light)

Today's volume of 22,044 shares is on pace to be much lighter than KRTX's 10-day average volume of 191,081 shares.

22,044

INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against HyreCar Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

5:20 pm ET October 15, 2021 (Newsfile) Print

Los Angeles, California--(Newsfile Corp. - October 15, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against HyreCar Inc. ("HyreCar" or "the Company") (NASDAQ: HYRE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between May 14, 2021 and August 10, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before October 26, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. HyreCar understated its insurance reserves. The Company consistently failed to pay valid insurance claims incurred before May 2021. The Company suffered from considerable expenses transitioning to a new third-party claims administrator. The Company failed to price appropriate risk into its insurance products leading to a higher claims rate. The Company had to completely overhaul its claims underwriting policies and procedures in the face of high claims severity and customer complaints. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about HyreCar, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99915

comtex tracking

COMTEX_395285842/2523/2021-10-15T17:20:58

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.